Who founded Alamarbio?

Alamarbio was founded by Yuling Luo, Steve Chen, Yiyuan Yin in 2018.

Who are Alamarbio's investors?

Alamarbio's investors include Illumina Ventures, Qiming Venture Partners, Samsara BioCapital.

Where is Alamarbio headquartered?

Alamarbio is headquartered in Fremont, US.

Alamarbio

Fremont, US · Founded 2018 · 243 employees on LinkedIn · 3 known investors

Find your way into Alamarbio

872 people in our graph share verified history with the Alamarbio team — schools, employers, funds. One of them is your warm intro.

Eric Lefkofskyunlockedknows Tod White · together at University of Michigan Law School (overlapped)

×2knows the team · via Northwestern University

knows the team · via NanoString Technologies, Inc.

×2knows the team · via Life Technologies

×2knows the team · via University of Michigan Law School

knows the team · via Hamilton College

Alamar Biosciences develops NULISA, an ultra-high-sensitivity, high-specificity technology for analyzing hundreds of protein biomarkers from small biofluid samples, building on the team's prior spatial genomics work (RNAscope). The company serves proteomics research and clinical drug development applications.

Biotech Deep Tech Healthtech

Founders & leadership

Alamarbio was founded in 2018 by Yuling Luo, Steve Chen, and Yiyuan Yin.

Yuling LuoinCo-founder, CEO and ChairInvestor at Unknown Investment Firm

Steve CheninCo-founder, COO and Director

Yiyuan YininCo-founder, VP of Technology

Tod White inPresidentTod White is President of Alamar Biosciences. He previously worked as a transactional attorney at an AmLaw 200 firm, served as General Counsel at a multinational life sciences company, and founded a boutique investment banking firm.

Justin McAnearinCFO

Xiao-Jun MaCTO

Steve Williams inCSOSteve Williams is Chief Scientific Officer of Alamar Biosciences. He has held leadership roles in biomarker development, translational medicine, and diagnostics across pharma, biotech, and clinical settings, including establishing biomarker programs and clinical assay operations, and has contributed to FDA guidance on biomarker qualification and co-founded the Biomarkers Consortium with FDA and FNIH.

Anna Berdine inSVP, MarketingAnna Berdine is SVP of Marketing at Alamar Biosciences, which develops NULISA, an ultra-high-sensitivity protein biomarker analysis technology for proteomics research and clinical drug development. She brings over 20 years of biotech experience in strategy, product management, marketing, and commercialization for both capital equipment and consumable businesses.

Alex Forrest-Hay inSVP of SalesAlex Forrest-Hay brings 26 years of sales experience across academic, government, healthcare, pharmaceutical, and commercial sectors, with 10 years in European markets and 16 years in North America leading global teams in life sciences, and holds expertise in genomics, transcriptomics, immuno-oncology, pathology, proteomics, and metabolomics. He serves as SVP of Sales at Alamar Biosciences, which develops the NULISA platform for high-sensitivity protein biomarker analysis from small biofluid samples.

Micah LitowinSVP, AI & Strategic Initiatives

Investors · 3

Illumina VenturesFoster City

Qiming Venture PartnersBeijing · $5M – $134M

Samsara BioCapitalPalo Alto

Competitors · 2

by search overlap

IQVIA22 shared keywordsIQVIA is a healthcare data and technology company that supports life sciences organizations in research, clinical development, and commercialization of medicines and medical solutions.

Quanterix22 shared keywordsQuanterix develops technology for highly sensitive detection of protein biomarkers using non-invasive sample types, aimed at early disease detection and prevention. The company serves the precision healthcare and life sciences research market with biomarker detection tools.

Companies competing with Alamarbio for the same Google search keywords, organic and paid, via search-intersection analysis.

Non-dilutive funding · 1 SBIR/STTR award

Federal grants — no equity taken

Agency	Phase	Year	Amount
National Institutes of Health (NIH)National Institutes of Health	Phase I	2020	$321.9K

Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.

Frequently asked questions

What does Alamarbio do?: Alamar Biosciences develops NULISA, an ultra-high-sensitivity, high-specificity technology for analyzing hundreds of protein biomarkers from small biofluid samples, building on the team's prior spatial genomics work (RNAscope). The company serves proteomics research and clinical drug development applications.
Who founded Alamarbio?: Alamarbio was founded by Yuling Luo, Steve Chen, Yiyuan Yin in 2018.
Who are Alamarbio's investors?: Alamarbio's investors include Illumina Ventures, Qiming Venture Partners, Samsara BioCapital.
Where is Alamarbio headquartered?: Alamarbio is headquartered in Fremont, US.